SecBot SecBot
8-K ·Filed Apr 21, 2026

ERAS

Erasca, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-165297
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The accelerated data readout is a positive catalyst; traders should position ahead of mid-May 2026 for potential volatility. A positive readout could validate the pan-RAS mechanism and significantly re-rate the stock, given ERAS-0015's potential in a high-unmet-need oncology space.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$22.41
T+0 close · Apr 21, 2026 · via day close
Latest settled
−15.13%
T+60 · $19.02
Vs SPY
−22.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $22.41entry
  2. T+1 · 7mo ago −3.39%α −4.41% · $21.65
  3. T+5 · 7mo ago −55.82%α −56.91% · $9.90
  4. T+20 · 6mo ago −54.17%α −59.09% · $10.27
  5. T+60 · 4mo ago −15.13%α −22.03% · $19.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca, Inc. updated guidance, narrowing the expected timing for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 trials to no later than mid-May 2026, an acceleration from prior 'first half of 2026' guidance. This clinical milestone is critical for validating the drug's efficacy in RAS-mutant solid tumors.

Key Facts

  • Erasca narrowed the anticipated Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May 2026, up from prior guidance of first half of 2026.
  • Data will come from two trials: AURORAS-1 (Erasca's trial in RAS-mutant solid tumors) and JYP0015M101 (conducted by licensor Joyo in China).
  • ERAS-0015 is a pan-RAS molecular glue, a novel mechanism targeting a key oncogenic pathway with high therapeutic potential.

Financial Impact

No direct financial impact disclosed. The event is a clinical milestone that could significantly influence future valuation and partnership potential.

pipeline valueR&D progressinvestor sentiment

Risk Factors

  • Clinical data may not meet efficacy or safety expectations, leading to a sharp decline.
  • The accelerated timeline increases near-term event risk and stock volatility.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-165297
Document: 0001193125-26-165297-index-headers.html0001193125-26-165297
Document: 0001193125-26-165297-index.html0001193125-26-165297
Document: 0001193125-26-165297.txt0001193125-26-165297

Track record

26 reports on ERAS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026